Phase 2 Stroke Trial, Recruiting NCT06857487 Sponsor: Dongzhimen Hospital, Beijing Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT06857487
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are admitted to hospital and have been diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel in the brain)
  • People whose stroke symptoms match a specific pattern described in Traditional Chinese Medicine (TCM) called "phlegm-heat syndrome" (confirm with trial site)
  • People whose brain scan (MRI) results or risk factor profile suggest they are at higher risk of their stroke symptoms getting worse in the early stages
  • People whose stroke started within the last 48 hours
  • People aged between 18 and 80 years old, of any gender
  • People (or their representative) who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who have received, or are planned to receive, clot-dissolving medication or a procedure to open the blocked blood vessel
  • People whose stroke may have been caused by a brain tumour, head injury, or a blood disorder, rather than a typical ischemic stroke
  • People who already needed significant help with daily activities before this stroke occurred
  • People who have a condition affecting their movement, such as severe joint disease
  • People with known serious liver or kidney problems, based on blood test results
  • People with severe difficulty speaking or a serious mental illness that would affect their ability to participate in assessments
  • People who are pregnant, possibly pregnant, or breastfeeding
  • People who are currently taking part in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dongzhimen Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
13 June 2025
Est. completion
24 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of early neurological deterioration within 7 days of onset

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov